# Phase 1/2 Precursor Cell: 42 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials in phase 1/2 for Precursor Cell Lymphoblastic Leukemia-Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials: 42 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/precursor-cell-lymphoblastic-leukemia-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 42
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| February 4, 2026 | NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class... | Novartis Pharmaceuticals | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387926) |
| January 21, 2026 | NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356154) |
| September 16, 2025 | NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Princess Maxima Center for Pediatric Oncology | Phase 1/2 | Not yet recruiting | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175415) |
| September 4, 2025 | NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar... | AstraZeneca | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155226) |
| August 7, 2025 | NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | AstraZeneca | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109219) |
| July 18, 2025 | NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A... | Zhujiang Hospital | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072494) |
| July 17, 2025 | NCT07070323 | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T... | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070323) |
| July 17, 2025 | NCT07070219 | A Study of CTD402 in T-ALL/LBL Patients | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070219) |
| June 6, 2025 | NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Acute Lymphocytic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008885) |
| July 1, 2024 | NCT06481735 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Acute Lymphocytic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481735) |
| April 15, 2024 | NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364423) |
| March 19, 2024 | NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06316856) |
| March 18, 2024 | NCT06316427 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06316427) |
| March 13, 2024 | NCT06308588 | Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06308588) |
| March 7, 2024 | NCT06299462 | PTCy and ATG for MSD and MUD Transplants | Instituto Nacional de Cancer, Brazil | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Non-hodgkin Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06299462) |
| January 19, 2024 | NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). | Essen Biotech | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06213636) |
| January 16, 2024 | NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or... | University of Chicago | Phase 1/2 | Recruiting | Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06207123) |
| January 16, 2024 | NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | Shenzhen TargetRx Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206174) |
| October 26, 2023 | NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma | University of Sao Paulo | Phase 1/2 | Recruiting | Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06101381) |
| October 3, 2023 | NCT06064903 | CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL | Bambino Gesù Hospital and Research Institute | Phase 1/2 | Recruiting | T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06064903) |
| May 8, 2023 | NCT05848687 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Lymphoblastic Leukemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05848687) |
| March 2, 2023 | NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory... | Princess Maxima Center for Pediatric Oncology | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent... | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05751044) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Princess Maxima Center for Pediatric Oncology | 4 |
| Beijing GoBroad Hospital | 3 |
| National Cancer Institute (NCI) | 2 |
| Chinese PLA General Hospital | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Fred Hutchinson Cancer Center | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| St. Jude Children's Research Hospital | 1 |
| MSD R&D (China) Co., Ltd. | 1 |
| University of Sao Paulo | 1 |
| Essen Biotech | 1 |
| M.D. Anderson Cancer Center | 1 |
| University of Chicago | 1 |
| University Hospital Heidelberg | 1 |
| [Sumitomo Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/sumitomo-pharma-america-inc) | 1 |
| PedAL BCU, LLC | 1 |
| Ottawa Hospital Research Institute | 1 |
| Instituto Nacional de Cancer, Brazil | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| Shenzhen University General Hospital | 1 |
| University of Alberta | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Bambino Gesù Hospital and Research Institute | 1 |
| [Syndax Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals) | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| China | 11 |
| France | 8 |
| Italy | 8 |
| Canada | 8 |
| Spain | 7 |
| United Kingdom | 7 |
| Australia | 6 |
| Netherlands | 6 |
| Germany | 6 |
| Israel | 5 |
| Belgium | 5 |
| South Korea | 4 |
| Denmark | 4 |
| Sweden | 4 |
| Taiwan | 3 |
| Austria | 3 |
| Finland | 3 |
| Ireland | 3 |
| Norway | 3 |
| Japan | 3 |
| Switzerland | 2 |
| Brazil | 2 |
| Puerto Rico | 2 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
- [Housing or property companies in the United States](https://specstream.ai/data/businesses/housing-or-property-companies/united-states)
- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
